Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CIR-0602K in Type 1 Diabetes Using Closed-loop Automated Insulin Delivery
NCT07186660Phase 2Recruiting
- Sponsor
- University of Virginia
- Start
- Feb 2026
- Primary completion
- Sep 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in type 1 diabetes mellitus (T1D) comparing CIR-0602K with Placebo (2 arms). Primary endpoint: Glucose Time-in-Range at 12 weeks. Started Feb 2026; status: recruiting.
02
Drugs
azemiglitazone
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT07186660.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07186660.